Equities research analysts at Nomura initiated coverage on shares of Retrophin (NASDAQ:RTRX) in a report issued on Monday, MarketBeat reports. The firm set a “buy” rating and a $57.00 price target on the biopharmaceutical company’s stock. Nomura’s price target would suggest a potential upside of 127.64% from the stock’s current price.

Several other research analysts have also recently weighed in on RTRX. BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a report on Tuesday, August 28th. ValuEngine upgraded shares of Retrophin from a “buy” rating to a “strong-buy” rating in a report on Wednesday, November 7th. Zacks Investment Research cut shares of Retrophin from a “hold” rating to a “strong sell” rating in a report on Thursday, November 8th. Jefferies Financial Group assumed coverage on shares of Retrophin in a report on Tuesday, October 30th. They issued a “buy” rating and a $44.00 price target for the company. Finally, Canaccord Genuity assumed coverage on shares of Retrophin in a report on Friday, August 17th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $48.00.

Retrophin stock opened at $25.04 on Monday. The company has a market capitalization of $1.04 billion, a PE ratio of -16.67 and a beta of 1.19. Retrophin has a twelve month low of $20.09 and a twelve month high of $33.00. The company has a quick ratio of 4.99, a current ratio of 5.04 and a debt-to-equity ratio of 0.60.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.39). The company had revenue of $40.70 million during the quarter, compared to analyst estimates of $44.36 million. Retrophin had a negative net margin of 69.38% and a negative return on equity of 35.43%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.15 EPS. As a group, equities research analysts predict that Retrophin will post -2.67 EPS for the current fiscal year.

In other news, SVP Elizabeth E. Reed sold 2,500 shares of the business’s stock in a transaction on Wednesday, November 14th. The shares were sold at an average price of $23.73, for a total value of $59,325.00. Following the sale, the senior vice president now owns 20,627 shares of the company’s stock, valued at $489,478.71. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Neil F. Mcfarlane sold 10,000 shares of the business’s stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $23.73, for a total transaction of $237,300.00. Following the completion of the sale, the chief operating officer now directly owns 29,476 shares in the company, valued at approximately $699,465.48. The disclosure for this sale can be found here. In the last three months, insiders sold 48,100 shares of company stock worth $1,247,658. 3.67% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. Trexquant Investment LP bought a new stake in shares of Retrophin in the second quarter worth $273,000. Hartford Investment Management Co. bought a new stake in shares of Retrophin in the second quarter worth $216,000. PNC Financial Services Group Inc. lifted its position in shares of Retrophin by 1,404.9% in the second quarter. PNC Financial Services Group Inc. now owns 272,328 shares of the biopharmaceutical company’s stock worth $7,424,000 after purchasing an additional 254,232 shares in the last quarter. Algert Global LLC bought a new stake in shares of Retrophin in the second quarter worth $358,000. Finally, Sei Investments Co. bought a new stake in shares of Retrophin in the second quarter worth $141,000. 98.15% of the stock is currently owned by institutional investors and hedge funds.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Read More: Price to Earnings Ratio (PE)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.